Intellia Therapeutics, INC 10-Q quarterly reports

Intellia Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its CRISPR-based gene editing programs for HAE and ATTR amyloidosis, alongside a net loss of $96.2 million.

Intellia Therapeutics reports reduced net loss but faces a clinical hold on its lead ATTR amyloidosis program, nex-z, following a patient death.

Intellia Therapeutics reports a narrower net loss in Q2 2025, driven by strategic restructuring and strong clinical progress in its lead gene editing programs for ATTR amyloidosis and hereditary angioedema.

Intellia Therapeutics announces its Q1 2025 financial results, showcasing ongoing clinical advancements in its CRISPR-based therapies for ATTR amyloidosis and hereditary angioedema.

Intellia Therapeutics' third quarter 2024 report highlights progress in clinical trials and financial updates, including a net loss of $135.7 million.

Intellia Therapeutics' second quarter 2024 results show a net loss, increased R&D spending, and progress in clinical trials for gene editing therapies.

Intellia Therapeutics reported its first quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.